Literature DB >> 3752699

Medical therapy of Mycobacterium avium-intracellulare pulmonary disease.

E T Etzkorn, S Aldarondo, C K McAllister, J Matthews, A J Ognibene.   

Abstract

Fifty-four patients meeting strict criteria for invasive pulmonary disease caused by Mycobacterium avium-intracellulare complex have been treated and followed at San Antonio State Chest Hospital during the past 15 yr. Chemotherapy with standard antituberculosis drugs was successful in effecting sputum conversion in 32 (59%) of the 54 patients. Regimens containing 2 drugs were successful in only 1 of 10 patients. If 3 or more drugs were given, 91% of those with moderately advanced cavitary disease and 64% of those with far advanced disease responded. There was no correlation between sputum conversion and use of a drug to which the organism exhibited susceptibility in vitro. No particular drug or combination of drugs was uniquely effective.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752699     DOI: 10.1164/arrd.1986.134.3.442

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  18 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Action of 1-isonicotinyl-2-palmitoyl hydrazine against the Mycobacterium avium complex and enhancement of its activity by m-fluorophenylalanine.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 4.  Risk-benefit assessment of therapies for Mycobacterium avium complex infections.

Authors:  D E Griffith
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

5.  Mycobacterium avium infection improved by microbial substitution of fungal infection.

Authors:  Shuichi Yano
Journal:  BMJ Case Rep       Date:  2010-10-21

6.  Low in vitro production of interferon-gamma and tumor necrosis factor-alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria.

Authors:  U Greinert; M Schlaak; S Rüsch-Gerdes; H D Flad; M Ernst
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

7.  Activities of fluoroquinolone, macrolide, and aminoglycoside drugs combined with inhibitors of glycosylation and fatty acid and peptide biosynthesis against Mycobacterium avium.

Authors:  W W Barrow; E L Wright; K S Goh; N Rastogi
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 9.  Mycobacterium avium complex: advances in therapy.

Authors:  D V Havlir
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

10.  Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.

Authors:  N Rastogi; K S Goh; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.